CRISPR stock: buy or sell?
December 6th, 2019
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR\u002FCas9)gene-editing platform in Switzerland.
Should I buy CRISPR stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading strategy that matches with your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
These 2 buy setups are elegible for CRISPR stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is CRISPR Therapeutics stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 8 ratings published for CRSP stock in the last 30 days. The general sentiment of these ratings is bullish for CRSP stock, with 5 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-1||Jefferies Financial Group||n/a||Buy|
|2019-7-31||Needham & Company LLC||n/a||Buy|
|2019-3-13||William Blair||n/a||Market Perform|
CRISPR stock analysis
After topping to all time highs on Dec 4th, CRISPR Therapeutics jumped 2.35% to $72.37.
CRISPR jumped 2.35% to $72.37 after topping to all time highs on Dec/4. In the last 39 days when CRSP stock price broke up the SMA200d line, it gained $32.52 (81.61%). In the last 4 days when SMA50d and SMA100d crossed up, CRSP price gained $0.72 per share (1.00%). On December/4, CRSP hit new all time highs, pushing higher previous ATH of $74.00 recorded on Nov/19. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
CRISPR reached new all time highs again this week, marking to $74.00. Shares closed at $72.37 and gained 1.00% during the week. Last week CRSP climbed a super good 13.19% in just one week. With this, it's been 4 climbing weeks in a row, soaring a 42.90%.
Since price and SMA40w lines crossed up late October, CRSP climbed $32.52 (81.61%). Since SMA20d and SMA40w crossed up by mid June, CRSP price climbed $29.49 per share (68.77%).
CRISPR stock price history
CRISPR IPO was on October 19th, 2016 at $15.00 per share1. Since then, CRSP stock surged a 382.50%, with an average of 127.50% per year. If you had invested right after CRSP's IPO a $1,000 in CRISPR stock in 2016, it would worth $3,825.00 today.
1: Adjusted price after possible price splits or reverse-splits.
CRISPR stock historical price chart
CRSP stock reached all-time highs on Dec 4th with a price of $74.00.
CRISPR stock price target is $59.40How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 5 price predictions for CRSP stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-1||Jefferies Financial Group||Initiates||n/a||$64.00||-|
|2019-7-31||Needham & Company LLC||Reiterates||n/a||$62.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, CRISPR Therapeutics reported its latest financial data, posting a great gain for the Earnings per Share (EPS). Analyst were expecting $-0.78 per share, but CRISPR Therapeutics posted $-0.92.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a scary correction of -92.38% to $3.12 M dollars. In the same way, its profit margin (compared to sales) collapsed to -5,281.08%, that is $-164.98 million.
|2015||$0.25 M||-||$-25.50 M-10325.1%||-|
|2016||$5.16 M||1,990.69%||$-23.18 M-448.8%||-9.12%|
|2017||$41 M||693.90%||$-68.36 M-166.7%||194.93%|
|2018||$3.12 M||-92.38%||$-164.98 M-5281.1%||141.35%|
Quarterly financial resultsCRISPR reported $0.12 M in sales for 2018-Q4, a -79.57% less compared to previous quarter. Reported quarter income marked $-47.59 M with a profit margin of -41,382.61%. Profit margin plummed a -32,375.33% compared to previous quarter when profit margin was -9,007.28%. When comparing revenues to same quarter last year, CRISPR Therapeutics sales marked a hair-raising drop down and plunged a -99.64%. Looking back to recent quarterly results, CRISPR posted 4 positive quarters in a row.
|2017-Q2||$3.58 M||-||$-22.32 M-623.5%||-|
|2017-Q3||$2.39 M||-33.32%||$-24.71 M-1035.1%||10.69%|
|2017-Q4||$32.33 M||1,254.21%||$0.14 M0.4%||-100.57%|
|2018-Q1||$1.36 M||-95.80%||$-28.30 M-2083.9%||-20,170.92%|
|2018-Q2||$1.09 M||-19.88%||$-38.38 M-3527.6%||35.62%|
|2018-Q3||$0.56 M||-48.25%||$-50.71 M-9007.3%||32.13%|
|2018-Q4||$0.12 M||-79.57%||$-47.59 M-41382.6%||-6.15%|
|2019-Q1||$0.33 M||185.22%||$-48.41 M-14758.5%||1.72%|
CRISPR ownershipWhen you are planning to buy shares of a stock, it's always worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For CRISPR Therapeutics, 41.38% of all outstanding shares are owned by its staff.
In case of CRISPR stock, 44.50% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CRSP stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related companies:
|Market cap||$4.1 B||$341.4 M||$188.6 M|
|Total shares||56.2 M||114.2 M||55.0 M|
|Float shares||34.4 M||96.5 M||41.5 M|
|- Institutional holdings (%)||44.5%||95.2%||72.8%|
|- Insider holdings (%)||41.4%||2.5%||0.2%|
|Shares in short selling||0.0%||0.0%||0.0%|
|Friday, December 6th, 2019|
|Day range||$70.57 - $72.70|
|Average true range||$5.42|
|50d mov avg||$50.48|
|100d mov avg||$49.18|
|200d mov avg||$44.77|
CRISPR performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare CRISPR to PDL BioPharma and Pieris Pharmaceuticals: